Schouw & Co (SCHO) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
23 Dec, 2025Executive summary
Revenue declined 7% to DKK 34.7 billion in 2024, mainly due to lower input costs and activity levels, but EBITDA reached a record high, up 3% to DKK 2.93 billion.
Cash flow from operations rose 44% to DKK 2.5 billion, and net working capital was reduced by DKK 450 million, with inventories down from DKK 8.0 billion to DKK 7.2 billion.
Net interest-bearing debt fell 15% to DKK 5,376 million, with leverage now well below 2x EBITDA.
Prudent investments and significant shareholder returns through dividends and buybacks, totaling DKK 644 million.
Financial highlights
Cash flow from operations rose 44% to DKK 2,553 million, and ROIC (excluding goodwill) improved by 0.2pp to 13.0%.
Net working capital settled at DKK 6.77 billion, with ongoing focus on further reductions.
NIBD/EBITDA improved from 2.2x to 1.8x year-over-year, within the target range of 1.0-2.5x.
CapEx in 2024 was DKK 685 million, with expectations for slightly higher or maintenance-focused CapEx in 2025.
Emissions (scope 1 and 2) reduced by 5% to 205,000 tonnes CO2e.
Outlook and guidance
Group turnover for 2025 is expected in the range of DKK 33.4-35.9 billion, with EBITDA guidance of DKK 2.82-3.12 billion and EBIT of DKK 1.68-1.98 billion.
CapEx in 2025 will focus on maintenance and finalizing ongoing projects, including upgrades in Fibertex Nonwovens.
Most portfolio businesses expect stable or improved EBITDA in 2025, except Fibertex Personal Care, which anticipates continued challenges.
Cautiously optimistic outlook for 2025, supported by a well-invested platform and strong customer relationships.
Latest events from Schouw & Co
- Record cash flow and EBITDA growth in most segments, with improved leverage and strong 2026 outlook.SCHO
Q4 20255 Mar 2026 - EBITDA guidance raised as margin gains offset revenue decline amid market headwinds.SCHO
Q2 20241 Feb 2026 - Revenue and EBITDA fell, but margins and cash flow held; BioMar IPO and cost cuts in focus.SCHO
Q3 202415 Jan 2026 - Q1 2025 revenue up 1%, EBITDA down 13%, guidance maintained, BioMar IPO prep advances.SCHO
Q1 202529 Nov 2025 - Stable Q2 with strong cash flow and narrowed guidance; segment outlooks mixed amid volatility.SCHO
Q2 202523 Nov 2025 - EBITDA rose 5% despite a 4% revenue drop, with narrowed guidance and ongoing restructuring.SCHO
Q3 202512 Nov 2025